Exact Sciences Corp. (EXAS) Colorectal Cancer Screening Technology Achieves 100% Sensitivity
Exact Sciences Corp. is a molecular diagnostics company focusing on colorectal cancer and detection and screening technology. Data regarding the company’s DNA methylation specific technology is available at the annual meeting of the American Association of Clinical Chemistry (AACC). The data demonstrates that the technology, using a combination of DNA methylation markers, detected colorectal cancers and precancers at 100 percent efficacy in a preliminary study with colorectal tissue. Kevin T. Conroy, president and CEO of Exact Sciences, said the results reflect the company’s stringent research efforts, and noted that the data’s milestone achievement. “The data being presented today at AACC…